Published: June 2020
Given the success of approved peptide therapeutics, such as Victoza® and Nplate®, the manufacturing demand has substantially increased causing many developers to rely on contract service providers
Roots Analysis has announced the addition of the Peptide Therapeutics: Contract API Manufacturing Market report to its list of offerings.
The inherent advantages of peptide therapeutics, such as small size, low immunogenicity and better cellular uptake, has led to a rise in interest in such interventions. This is anticipated to create significant opportunities for CMOs offering peptide manufacturing services. However, in order to meet the current and future demand, contract manufacturers may need to strengthen their respective capabilities and expand available capacities.
To order this 250+ page report, which features 100+ figures and 110+ tables, please visit https://www.rootsanalysis.com/reports/peptide-therapeutics-manufacturing/305.html#overview
Over 50 CMOs presently claim to offer manufacturing services for peptide therapeutics
The peptide API contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which collectively represent more than 70% of industry stakeholders. It is worth highlighting that around 60% CMOs claim to have the necessary capabilities to manufacture peptides across all scales of operation (preclinical, clinical and commercial).
More than 80% of therapeutic peptides are manufactured using the chemical synthesis technique
Amongst chemical approaches, solid phase synthesis emerged as the most popular technique, being used by over 40% CMOs for manufacturing of peptides. Further, more than 30% CMOs claim to have capabilities to produce cyclic peptides. In addition, over 50% peptide purification is done through HPLC.
North America is considered to be a key manufacturing hub for peptide-based products
More than 70 peptide manufacturing facilities have been established by various players, across the globe; of these, 38% are located in North America, followed by those based in Europe. Similarly, China is one of the popular peptide manufacturing hubs in the Asia Pacific.
500+ active clinical trials have evaluated / are evaluating various peptide-based interventions
In 2019 alone, 124 clinical trials focused on peptide therapeutics were registered, of which, 90% are active. Further, in the same year more than 18,000 patients were recruited across the globe. It is worth noting that over 60% trials are evaluating peptide therapeutics intended for the treatment of oncological disorders, followed by those being conducted for molecules targeting metabolic disorders (14%).
Demand for peptide therapeutics is anticipated to grow at a CAGR of 10%, during 2020-2025
Given the fact that there are a number of peptide therapeutics available in the market, the commercial manufacturing demand for such products is significantly higher than the clinical demand. Further, over half of the global manufacturing demand for peptides therapeutics is anticipated to be generated in North America.
Current, global peptide manufacturing capacity is estimated to be more than 0.15 million L
It is worth mentioning that majority of the overall capacity is captured by large and very large CMOs. Further, in terms of geography, most of the current peptide manufacturing capacity is installed in facilities based in North America.
North America and Europe are anticipated to capture over 60% of the market share (in terms of service revenues) by 2030
It is worth noting that the market in Europe is anticipated to grow at a relatively faster rate (12.1%). Further, presently, more than 80% of the revenue is expected to be generated through manufacturing of commercial peptides, and this trend is unlikely to change significantly in short to mid-term.
You Can Download Free Sample PDF Copy of This Report At:
The USD 3.2 billion (by 2030) financial opportunity within the peptide therapeutics contract API manufacturing market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom peptide therapeutics developers are increasingly outsourcing their manufacturing operations to contract service providers, owing to various factors, such as the complex nature of the overall process, and the high investments associated with setting up of in-house expertise. The report includes detailed transcripts of a survey held with the following experts:
The research covers profiles of key players (listed below); each profile features an overview of the company, information related to its peptide manufacturing focused service portfolio, manufacturing facilities and capabilities, and an informed future outlook.
For additional details, please email at firstname.lastname@example.org
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES